Skin cancer vaccine trials are successful.

According to an announcement published in the journal Nature, American scientists have successfully tested a vaccine against skin cancer.

This skin cancer vaccine, called NeoVax, contains up to 20 cancer antigens. Unlike traditional vaccines that prevent the disease, NeoVax aims to prevent the return of malignant skin cancer cells after melanoma has been surgically removed.

NeoVax was administered to a group of six skin cancer patients who had undergone surgery to remove melanoma. Patrick Ott, co-author of the skin cancer vaccine study at the Dana-Farber Cancer Institute in Boston, stated that NeoVax was effective, safe, and generated an immune response in all vaccinated patients. Typically, about half of cancer patients experience recurrence within two years of treatment. However, after 25 months, four patients in the trial group did not experience melanoma recurrence.

This is a positive result, but it is not yet complete. The number of patients treated is quite low, so there is still a possibility that patients who do not receive the vaccine may not experience a recurrence of cancer.

A vaccine for prostate cancer is currently available, but it is not widely used. Other vaccines for lung, bladder, and skin cancer are undergoing phase 2 trials in combination with another treatment drug.

NeoVax's initial success has confirmed the potential of cancer treatment using vaccines. Researchers will continue with the next phase of testing on larger groups of participants to confirm the effectiveness of these vaccines.

According to VOV